JP2024508671A5 - - Google Patents
Info
- Publication number
- JP2024508671A5 JP2024508671A5 JP2023547585A JP2023547585A JP2024508671A5 JP 2024508671 A5 JP2024508671 A5 JP 2024508671A5 JP 2023547585 A JP2023547585 A JP 2023547585A JP 2023547585 A JP2023547585 A JP 2023547585A JP 2024508671 A5 JP2024508671 A5 JP 2024508671A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- cdr
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2021/076626 WO2022170619A1 (en) | 2021-02-11 | 2021-02-11 | Anti-cd3 antibodies and methods of use thereof |
| CNPCT/CN2021/076626 | 2021-02-11 | ||
| CNPCT/CN2021/109057 | 2021-07-28 | ||
| PCT/CN2021/109057 WO2022170740A1 (en) | 2021-02-11 | 2021-07-28 | Anti-cd3 antibodies and methods of use thereof |
| PCT/CN2022/076000 WO2022171192A1 (en) | 2021-02-11 | 2022-02-11 | Anti-cd3 antibodies and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024508671A JP2024508671A (ja) | 2024-02-28 |
| JP2024508671A5 true JP2024508671A5 (enExample) | 2024-12-23 |
| JP7902187B2 JP7902187B2 (ja) | 2026-08-07 |
Family
ID=82837474
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023547585A Active JP7902187B2 (ja) | 2021-02-11 | 2022-02-11 | 抗ｃｄ３抗体及びその使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250326860A1 (enExample) |
| EP (1) | EP4291578A4 (enExample) |
| JP (1) | JP7902187B2 (enExample) |
| KR (1) | KR20230162930A (enExample) |
| CN (1) | CN117255801A (enExample) |
| AU (1) | AU2022219133A1 (enExample) |
| CA (1) | CA3206603A1 (enExample) |
| TW (1) | TW202246337A (enExample) |
| WO (3) | WO2022170619A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111511762B (zh) | 2017-08-21 | 2025-05-06 | 天演药业公司 | 抗cd137分子及其用途 |
| TWI920054B (zh) * | 2020-01-23 | 2026-04-01 | 瑞士商天演藥業公司 | 具有Ｆｃ突變之異二聚蛋白質 |
| WO2023192973A1 (en) * | 2022-04-01 | 2023-10-05 | Cytomx Therapeutics, Inc. | Activatable multispecific molecules and methods of use thereof |
| AU2023338559A1 (en) * | 2022-09-09 | 2025-03-27 | Adagene Pte. Ltd. | Activatable anti-ctla4 antibodies for treating cancer |
| EP4594353A1 (en) * | 2022-09-28 | 2025-08-06 | F. Hoffmann-La Roche AG | Improved protease-activatable t cell bispecific antibodies |
| TW202436345A (zh) * | 2023-03-06 | 2024-09-16 | 瑞士商百濟神州瑞士有限責任公司 | 抗ｃｄ３多特異性抗體及使用方法 |
| WO2024212151A1 (en) * | 2023-04-13 | 2024-10-17 | Adagene Pte. Ltd. | Masked antibodies, libraries and methods of use |
| CN122341642A (zh) | 2023-09-21 | 2026-07-03 | 多曼治疗学公司 | 抗ccr8单克隆抗体及其治疗用途 |
| WO2025061993A1 (en) | 2023-09-21 | 2025-03-27 | Domain Therapeutics | Anti-ccr8 monoclonal antibodies and their therapeutic use |
| WO2025199278A2 (en) * | 2024-03-20 | 2025-09-25 | Regeneron Pharmaceuticals, Inc. | Masked multispecific antigen-binding molecules with cleavable linkers |
| WO2026006496A1 (en) * | 2024-06-25 | 2026-01-02 | Alloy Therapeutics, Inc. | Anti-cd3 antibodies and uses thereof |
| WO2026002279A1 (en) * | 2024-06-28 | 2026-01-02 | Vibrant Pharma Limited | Mask peptide, cleavable substrate, multispecific antibodies and uses thereof |
| WO2026024841A1 (en) * | 2024-07-24 | 2026-01-29 | Astellas Us Llc | Bispecific antibodies that bind cd3 and muc1 and methods of use thereof |
| CN118562015B (zh) * | 2024-08-01 | 2024-12-06 | 广州爱思迈生物医药科技有限公司 | 一种针对cd20/cd3的双特异性抗体及其制备方法和应用 |
| WO2026159103A1 (en) * | 2025-01-23 | 2026-07-30 | F. Hoffmann-La Roche Ag | Antibodies binding to cd3 |
| WO2026159100A1 (en) * | 2025-01-23 | 2026-07-30 | F. Hoffmann-La Roche Ag | Antibodies binding to cd3 |
| WO2026159108A1 (en) * | 2025-01-23 | 2026-07-30 | F. Hoffmann-La Roche Ag | Antibodies binding to cd3 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2190861A4 (en) * | 2007-08-22 | 2011-03-30 | Univ California | ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE |
| EP3543256A1 (en) * | 2009-01-12 | 2019-09-25 | Cytomx Therapeutics Inc. | Modified antibody compositions, methods of making and using thereof |
| GB201203442D0 (en) * | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| KR102391731B1 (ko) * | 2013-01-14 | 2022-04-27 | 젠코어 인코포레이티드 | 신규한 이형이량체 단백질 |
| JP6693872B2 (ja) * | 2013-07-25 | 2020-05-13 | シトムクス セラピューティクス，インコーポレイティド | 多重特異性抗体、多重特異性活性化可能抗体、及びそれらの使用方法 |
| CA2955947A1 (en) * | 2014-07-25 | 2016-01-28 | Cytomx Therapeutics, Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
| WO2016115274A1 (en) * | 2015-01-14 | 2016-07-21 | Compass Therapeutics Llc | Multispecific immunomodulatory antigen-binding constructs |
| JP7082484B2 (ja) * | 2015-04-01 | 2022-06-08 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
| EP3778640A1 (en) * | 2015-05-01 | 2021-02-17 | Genentech, Inc. | Masked anti-cd3 antibodies and methods of use |
| US20160362469A1 (en) * | 2015-06-12 | 2016-12-15 | Tianxin Wang | Methods for protein modification in pharmaceutical applications |
| US20190031785A1 (en) * | 2016-01-13 | 2019-01-31 | Compass Therapeutics Llc | Multispecific immunomodulatory antigen-binding constructs |
| JP7015244B2 (ja) | 2016-03-22 | 2022-02-02 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | プロテアーゼ活性化ｔ細胞二重特異性分子 |
| WO2017162587A1 (en) * | 2016-03-22 | 2017-09-28 | F. Hoffmann-La Roche Ag | Protease-activated t cell bispecific molecules |
| WO2018026942A1 (en) * | 2016-08-02 | 2018-02-08 | Merrimack Pharmaceuticals, Inc. | Heteromeric polypeptides |
| CN111247171A (zh) * | 2017-10-14 | 2020-06-05 | 西托姆克斯治疗公司 | 抗体、可活化抗体、双特异性抗体和双特异性可活化抗体及其使用方法 |
| KR20260039804A (ko) | 2017-12-21 | 2026-03-20 | 아뮤닉스 파마슈티컬스, 인크. | 유리 세그먼트 및 이것을 포함하는 결합 조성물 |
| WO2019148445A1 (en) * | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
| CN115093481A (zh) * | 2019-01-28 | 2022-09-23 | 正大天晴药业集团股份有限公司 | 新型双特异性cd3/cd20多肽复合物 |
| EP3959237A1 (en) * | 2019-04-25 | 2022-03-02 | F. Hoffmann-La Roche AG | Therapeutic multispecific polypeptides activated by polypeptide chain exchange |
| WO2020232303A1 (en) * | 2019-05-14 | 2020-11-19 | Harpoon Therapeutics, Inc. | EpCAM BINDING PROTEINS AND METHODS OF USE |
| WO2020264200A1 (en) * | 2019-06-26 | 2020-12-30 | Amunix Pharmceuticals, Inc. | Cd3 antigen binding fragments and compositions comprising same |
| TWI920054B (zh) * | 2020-01-23 | 2026-04-01 | 瑞士商天演藥業公司 | 具有Ｆｃ突變之異二聚蛋白質 |
| CN111995685B (zh) * | 2020-04-30 | 2022-03-08 | 中国科学院上海药物研究所 | 一种靶向her2和pd-1的双特异性抗体及其应用 |
-
2021
- 2021-02-11 WO PCT/CN2021/076626 patent/WO2022170619A1/en not_active Ceased
- 2021-07-28 WO PCT/CN2021/109057 patent/WO2022170740A1/en not_active Ceased
-
2022
- 2022-02-11 AU AU2022219133A patent/AU2022219133A1/en active Pending
- 2022-02-11 US US18/546,246 patent/US20250326860A1/en active Pending
- 2022-02-11 CA CA3206603A patent/CA3206603A1/en active Pending
- 2022-02-11 JP JP2023547585A patent/JP7902187B2/ja active Active
- 2022-02-11 KR KR1020237030742A patent/KR20230162930A/ko active Pending
- 2022-02-11 WO PCT/CN2022/076000 patent/WO2022171192A1/en not_active Ceased
- 2022-02-11 CN CN202280025216.6A patent/CN117255801A/zh active Pending
- 2022-02-11 TW TW111105162A patent/TW202246337A/zh unknown
- 2022-02-11 EP EP22752352.9A patent/EP4291578A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021534096A5 (enExample) | ||
| JP2025160226A5 (enExample) | ||
| JP2021503455A5 (enExample) | ||
| JP2023538945A5 (enExample) | ||
| JP2019122405A5 (enExample) | ||
| IL276903B1 (en) | Bispecific egfr/cd16 antigen-binding protein | |
| JP2023511376A5 (enExample) | ||
| PE20221511A1 (es) | Anticuerpos anti-ly6g6d y metodos de uso | |
| JP2021520832A5 (enExample) | ||
| JP2014519322A5 (enExample) | ||
| JP2013091655A5 (enExample) | ||
| JP2024501539A5 (enExample) | ||
| JP2020524661A5 (enExample) | ||
| IL277575B2 (en) | Antibodies for chelated radionuclides | |
| JP2022545647A5 (enExample) | ||
| RU2018128414A (ru) | Новое psma-связывающее антитело и его применения | |
| US20240117035A1 (en) | Cldn18.2/cd3 bispecific antibodies for the therapy of cldn18.2-expressing solid tumors | |
| JP2021533159A5 (enExample) | ||
| JP2023519962A5 (enExample) | ||
| JP2021522347A5 (enExample) | ||
| KR20200013233A (ko) | 신규 항 cd3 항체 | |
| JP2022504826A5 (enExample) | ||
| JP2022500455A5 (enExample) | ||
| JP2024543822A5 (enExample) | ||
| JP2023518408A5 (enExample) |